Cenegermin

Cenegermin is a lab-engineered recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis.

• Cenegermin is available under the following different brand names: Oxervate

Common side effects of Cenegermin include:

• eye pain
• eye redness
• eye inflammation
• increased tearing

Serious side effects of Cenegermin include:

• none

Rare side effects of Cenegermin include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, light-headedness, or passing out

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult and pediatric dosage

Ophthalmic solution

• 0.002% (20 mcg/mL)

Neurotrophic Keratitis

Adult dosage

• Instill 1 drop in affected eye(s), 6 times a day at 2-hour intervals for 8 weeks.

Pediatric dosage

Neurotrophic Keratitis

• Note: Safety and effectiveness have been established in the pediatric population; use in children is supported by evidence from adequate and well-controlled trials in adults with additional safety data in children aged 2 years and older
• Children aged 2 years and older: Instill 1 drop in affected eye(s), 6 times a day at 2-hour intervals for 8 weeks

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Cenegermin has no noted severe interactions with any other drugs.
• Cenegermin has no noted serious interactions with any other drugs.
• Cenegermin has no noted moderate interactions with any other drugs.
• Cenegermin has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions, concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Cenegermin?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Cenegermin?”

Cautions

• Remove contact lenses before application; the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin onto the area of the corneal lesion
• Mild-to-moderate eye discomfort (eg, eye pain during treatment); advise patients to contact their doctor if a more serious eye reaction occurs

Pregnancy and Lactation

• There are no data from the use in pregnant women to inform any drug-associated risks
• Lactation
  • Unknown if distributed in human breast milk
  • Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition